Understanding how RNA oxidation affects the onset and progression of ALS
Elucidating the role of RNA oxidation on amyotrophic lateral sclerosis onset and progression
This study is looking at how changes in RNA might contribute to ALS, by checking if oxidative stress is a cause or a result of the disease, and it’s for anyone interested in finding new ways to treat ALS.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11006360 on NIH RePORTER |
What this research studies
This research investigates the role of RNA oxidation in the development and progression of Amyotrophic Lateral Sclerosis (ALS). It aims to determine whether oxidative stress is a cause or consequence of the disease by examining the levels of oxidized RNA in motor neurons. The study will utilize induced pluripotent stem cell (iPSC)-derived motor neurons to identify RNA targets affected by oxidative stress and the role of RNA Binding Proteins (RBPs) in this process. By understanding these mechanisms, the research seeks to uncover potential therapeutic targets for ALS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Amyotrophic Lateral Sclerosis or those at risk of developing the condition.
Not a fit: Patients with other neurodegenerative diseases unrelated to ALS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights and treatments for patients with ALS by targeting the mechanisms of RNA oxidation.
How similar studies have performed: Other research has shown promising results in understanding oxidative stress in neurodegenerative diseases, but the specific focus on RNA oxidation in ALS is relatively novel.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Chaim, Isaac Alexander — University of California, San Diego
- Study coordinator: Chaim, Isaac Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.